Janus Henderson Group PLC Increases Stock Position in Kenvue Inc. (NYSE:KVUE)

Janus Henderson Group PLC boosted its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 20.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 263,969 shares of the company's stock after acquiring an additional 44,393 shares during the period. Janus Henderson Group PLC's holdings in Kenvue were worth $5,640,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of KVUE. Kiley Juergens Wealth Management LLC grew its stake in shares of Kenvue by 1.9% in the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company's stock worth $579,000 after purchasing an additional 500 shares during the last quarter. Principle Wealth Partners LLC grew its position in shares of Kenvue by 3.7% in the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock worth $303,000 after buying an additional 500 shares during the last quarter. White Pine Capital LLC increased its stake in shares of Kenvue by 1.0% during the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company's stock valued at $1,165,000 after buying an additional 542 shares during the period. Deseret Mutual Benefit Administrators increased its stake in shares of Kenvue by 29.0% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock valued at $54,000 after buying an additional 568 shares during the period. Finally, SRS Capital Advisors Inc. raised its holdings in shares of Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after acquiring an additional 571 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on KVUE. Canaccord Genuity Group boosted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Citigroup lifted their target price on shares of Kenvue from $22.00 to $24.50 and gave the company a "neutral" rating in a research note on Friday, May 9th. Royal Bank of Canada reiterated a "sector perform" rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. UBS Group raised their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Friday, May 9th. Finally, Evercore ISI began coverage on Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective on the stock. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $25.33.

Kenvue Stock Down 2.1%

Shares of KVUE traded down $0.52 during mid-day trading on Thursday, reaching $23.49. The company had a trading volume of 13,277,432 shares, compared to its average volume of 16,420,319. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $45.06 billion, a price-to-earnings ratio of 44.31, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The firm has a 50-day moving average price of $23.22 and a 200 day moving average price of $22.62. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The business had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. During the same quarter in the previous year, the business earned $0.28 earnings per share. The firm's quarterly revenue was down 3.9% compared to the same quarter last year. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.49%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue's payout ratio is 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.